Literature DB >> 17189537

Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults.

Gary P Van Guilder1, Greta L Hoetzer, Jared J Greiner, Brian L Stauffer, Christopher A Desouza.   

Abstract

OBJECTIVE: Both obesity and the metabolic syndrome (MetS) have been independently linked with increased oxidative and inflammatory stress. This study tested the hypothesis that obesity with MetS is associated with greater oxidative and inflammatory burden compared with obesity alone. RESEARCH METHODS AND PROCEDURES: Forty-eight normal-weight and 40 obese (20 without MetS; 20 with MetS) adults were studied. MetS was defined according to National Cholesterol Education Program Adult Treatment Panel III criteria. Plasma concentrations of oxidized low-density lipoprotein, C-reactive protein, tumor necrosis factor-alpha, interleukin (IL)-6, and IL-18 were determined by enzyme immunoassay.
RESULTS: Plasma biomarkers of oxidative stress and inflammation were lowest in normal-weight controls. Of note, obese MetS adults demonstrated significantly higher plasma concentrations of oxidized low-density lipoprotein (62.3 +/- 3.2 vs. 54.0 +/- 4.0 U/L; p < 0.05), C-reactive protein (3.0 +/- 0.6 vs. 1.5 +/- 0.3 mg/L; p < 0.01), tumor necrosis factor-alpha (2.1 +/- 0.1 vs. 1.6 +/- 0.1 pg/mL; p < 0.05), IL-6 (2.8 +/- 0.4 vs. 1.4 +/- 0.2 pg/mL; p < 0.01), and IL-18 (253 +/- 16 vs. 199 +/- 16 pg/mL; p < 0.01), compared with obese adults without MetS. DISCUSSION: These results suggest that MetS heightens oxidative stress and inflammatory burden in obese adults. Increased oxidative and inflammatory stress may contribute to the greater risk of coronary heart disease and cerebrovascular disease in obese adults with MetS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17189537     DOI: 10.1038/oby.2006.248

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  69 in total

Review 1.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

Review 2.  Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training.

Authors:  Christian K Roberts; Andrea L Hevener; R James Barnard
Journal:  Compr Physiol       Date:  2013-01       Impact factor: 9.090

3.  Metabolic syndrome and endothelin-1 mediated vasoconstrictor tone in overweight/obese adults.

Authors:  Natalia G Rocha; Danielle L Templeton; Jared J Greiner; Brian L Stauffer; Christopher A DeSouza
Journal:  Metabolism       Date:  2014-04-18       Impact factor: 8.694

4.  Nitric oxide-mediated endothlium-dependent vasodilation is impaired with borderline high-LDL cholesterol.

Authors:  Kyle J Diehl; Brian L Stauffer; Jared J Greiner; Brian R Weil; Christopher A DeSouza
Journal:  Clin Transl Sci       Date:  2012-02-23       Impact factor: 4.689

5.  Oxidative stress in the external intercostal muscles of patients with obstructive sleep apnoea.

Authors:  Esther Barreiro; Adam Nowinski; Joaquim Gea; Pawel Sliwinski
Journal:  Thorax       Date:  2007-06-15       Impact factor: 9.139

6.  Cyclooxygenase-derived vasoconstriction restrains hypoxia-mediated cerebral vasodilation in young adults with metabolic syndrome.

Authors:  John W Harrell; William G Schrage
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-11-08       Impact factor: 4.733

7.  Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists.

Authors:  Gary P Van Guilder; Brian L Stauffer; Jared J Greiner; Christopher A Desouza
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-02-15       Impact factor: 4.733

Review 8.  The role of interleukin-18 in the metabolic syndrome.

Authors:  Marius Trøseid; Ingebjørg Seljeflot; Harald Arnesen
Journal:  Cardiovasc Diabetol       Date:  2010-03-23       Impact factor: 9.951

9.  Increased inflammation, reduced plasma phospholipid eicosapentaenoic acid and reduced antioxidant potential of treated hypertensive patients with metabolic syndrome.

Authors:  Min-Jeong Shin; Eugene Shim; Borum Kang; Sungha Park; Sang-Hak Lee; Chi Young Shim; Eunju Park; Namsik Chung
Journal:  Yonsei Med J       Date:  2009-12-18       Impact factor: 2.759

10.  DASH lowers blood pressure in obese hypertensives beyond potassium, magnesium and fibre.

Authors:  Y Al-Solaiman; A Jesri; W K Mountford; D T Lackland; Y Zhao; B M Egan
Journal:  J Hum Hypertens       Date:  2009-07-23       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.